APR-246 Combo Treatment in TP53-Mutant Relapsed/Refractory NHL

(MedPage Today) -- At December's American Society of Hematology virtual annual meeting, researchers announced an upcoming phase I study that will evaluate the efficacy and safety of APR-246 (eprenetapopt) in combination with ibrutinib (Imbruvica...